Sledge GW, Toi M, Neven P, et al. MONARCH 2: Abemaciclib in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer who progressed on endocrine therapy. J Clin Oncol. 2017;35 (suppl; abstr 1000).
OLVG start met immunotherapie voor long- en niercelkanker
jul 2017 | Longoncologie, Uro-oncologie